Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 5/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922604 | 0.93 | CDK9 (0.37) | PDE5AHDAC1HDAC6CDK9CCNT1 | |
| SCHEMBL12197325 | 0.93 | CTSL (0.34) | CTSLCTSSCTSKPDE5AHDAC1 | |
| SCHEMBL14922668 | 0.91 | CDK9 (0.34) | PDE5AHDAC1HDAC6CDK9CCNT1 | |
| SCHEMBL12197344 | 0.91 | CDK9 (0.31) | CTSLCTSSCTSKCDK9CCNT1 | |
| SCHEMBL12197470 | 0.90 | CTSL (0.33) | CTSLCTSSCTSK | |
| SCHEMBL12197442 | 0.90 | CTSL (0.33) | CTSLCTSSCTSK | |
| SCHEMBL14922622 | 0.90 | CDK9 (0.34) | PDE5AHDAC1HDAC6CDK9CCNT1 | |
| SCHEMBL12197328 | 0.89 | CDK9 (0.38) | PDE5AHDAC1HDAC6CDK9CCNT1 | |
| SCHEMBL12197196 | 0.89 | CDK9 (0.38) | PDE5AHDAC1HDAC6CDK9CCNT1 | |
| SCHEMBL12197218 | 0.89 | CTSL (0.41) | CTSLCTSSCTSKPDE5AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | CTSL 3768/4885CTSS 2260/4885CTSK 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.